Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03409744 · ClinicalTrials.gov registry record · Phase 3
Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
A Phase 3 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 116
- Enrollment target
NCT03409744 is a Phase 3 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 116 participants.
The verdict
NCT03409744, a Phase 3 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 116 participants
- Enrollment target
Study Summary
The primary objectives of the study are: * To evaluate the long-term safety and tolerability of evinacumab in patients with Homozygous Familial Hypercholesterolemia (HoFH) * To evaluate the long-term safety and tolerability of evinacumab in adolescent patients with HoFH The secondary objectives of the study are: * To evaluate the effect of evinacumab on lipid parameters in patients with HoFH * To evaluate the effect of evinacumab on lipid parameters in adolescent patients with HoFH * To evaluate the potential development of anti-evinacumab antibodies
Interventions
- DRUG evinacumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2018-03-13 |
| Est. Completion | 2023-04-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03409744
The ClinicalTrials.gov registry entry for NCT03409744 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which evinacumab is the first listed.
NCT03409744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03409744 about?
NCT03409744 is a clinical study titled "Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia". The primary objectives of the study are: * To evaluate the long-term safety and tolerability of evinacumab in patients with Homozygous Familial Hypercholesterolemia (HoFH) * To evaluate the long-term safety and tolerability of evinacumab in adolescent patients with HoFH The secondary objectives of...
What is the current status of trial NCT03409744?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 116 participants. The study started on 2018-03-13. Estimated completion is 2023-04-13.
What interventions are being tested in trial NCT03409744?
The interventions under investigation include: evinacumab (DRUG).
Who is sponsoring clinical trial NCT03409744?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.